<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435980</url>
  </required_header>
  <id_info>
    <org_study_id>the south west Hospital2</org_study_id>
    <nct_id>NCT01435980</nct_id>
  </id_info>
  <brief_title>Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes</brief_title>
  <official_title>Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wu Qinan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To investigate the treatment effect between Gastric Bypass and Exenatide in Type
      2 Diabetes in our hospital, in order to investigate the possible mechanism of Gastric Bypass
      and Exenatide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:

      60 Type 2 diabetes in our hospital will divide into 3 groups: group A (20 patients who give
      basal treatment), group B (20 patients who give basal and Exenatide treatment, group C（20
      patients who give basal and Gastric Bypass treatment). The age, height, weight, blood
      glucose, glycosylated hemoglobin A1c（HbA1c）,homeostasis model assessment(HOMA-IR), lipid,
      blood pressure, course of disease, ejection fraction (EF), fractional shortening(FS),
      diameter of left ventricle in late diastolic stage(LVEDd), the thickness of the ventricular
      septa（IVSD) and the posterior wall of the right ventricle in late diastolic stage (LVPWd)
      will record respectively. Left ventricular mass index (LVMI), relative wall thickness (RWT)
      will calculate and High-sensitive C-reactive protein (HsCRP), adiponectin and Tumor necrosis
      factor-α（TNF-α） will detect as Baseline. After each group's treatment, Change from baseline
      of all indexes will record, Multifactor logistic regression will be analyzed the correlations
      between each positive indexes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical events</measure>
    <time_frame>1 year</time_frame>
    <description>Participant with stroke or Myocardial infarction or acute diabetic complication or Liver and renal failure or death or other Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>echocardiography</measure>
    <time_frame>1 year</time_frame>
    <description>Left ventricular mass index (LVMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiography</measure>
    <time_frame>1 year</time_frame>
    <description>relative wall thickness (RWT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood testing</measure>
    <time_frame>1 year</time_frame>
    <description>High-sensitive C-reactive protein (HsCRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood testing</measure>
    <time_frame>1 year</time_frame>
    <description>homeostasis model assessment(HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood testing</measure>
    <time_frame>1 year</time_frame>
    <description>adiponectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure monitoring</measure>
    <time_frame>1 month</time_frame>
    <description>blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood testing</measure>
    <time_frame>1 year</time_frame>
    <description>glycosylated hemoglobin A1c（HbA1c）</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>basal treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>basal treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric Bypass</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>basal treatment and Gastric Bypass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>basal treatment and Exenatide</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastric Bypass</intervention_name>
    <description>basal treatment and Gastric Bypass</description>
    <arm_group_label>Gastric Bypass</arm_group_label>
    <other_name>basal treatment + Gastric Bypass</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>basal treatment and Exenatide</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>basal treatment + Exenatide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. BMI ≥ 35kg/m2, With Type 2 Diabetes;

          2. BMI32-34.9kg/m2, With Type 2 Diabetes, Insulin Therapy in Combination With Oral
             Administration of Drugs for 6 Months and HbA1c ≥ 7%;

          3. Between the Ages of 18-60 Years;

          4. Course of Type 2 Diabetes ≤ 5 Years;

          5. ICA, IAA, GAD Are Negative , C-peptide Level is Not Less Than 0.3mg / L;

        Exclusion Criteria:

          1. non-diabetic patients , type 1 diabetes (serum insulin antibodies (ICA) or glutamic
             acid decarboxylase antibodies (GADA)-positive autoimmune diabetes), special type of
             diabetes, gestational diabetes;

          2. patients who had liver or renal failure

          3. severe infections in patients and patients who had cerebrovascular disease

          4. patients who had heart failure

          5. fasting serum insulin or 2-hour postprandial serum insulin were lower than normal
             (&lt;20mmol / L)

          6. course of diabetes&gt; 5 years or age&gt; 60 years or age &lt;18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>liang zi wen, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>wu qi nan, master</last_name>
    <phone>13452867542</phone>
    <phone_ext>02368765216</phone_ext>
    <email>wqn11@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Endocrine Department, the south west Hospital of the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wu qi nan, master</last_name>
      <phone>13452867542</phone>
      <phone_ext>02368765216</phone_ext>
      <email>wqn11@126.com</email>
    </contact>
    <investigator>
      <last_name>liang zi wen, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Wu Qinan</investigator_full_name>
    <investigator_title>Third Military Medical University</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>Gastric Bypass</keyword>
  <keyword>GLP-1</keyword>
  <keyword>adiponectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

